- Home
- PYPD vs ANTX Comparison
PYPD vs ANTX Comparison
Compare PYPD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- ANTX
- Stock Information
- Founded
- PYPD 2008
- ANTX 2017
- Country
- PYPD Israel
- ANTX United States
- Employees
- PYPD N/A
- ANTX N/A
- Industry
- PYPD Medical/Dental Instruments
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- ANTX Health Care
- Exchange
- PYPD Nasdaq
- ANTX Nasdaq
- Market Cap
- PYPD 36.0M
- ANTX 33.2M
- IPO Year
- PYPD 2020
- ANTX 2022
- Fundamental
- Price
- PYPD $3.66
- ANTX $1.09
- Analyst Decision
- PYPD Strong Buy
- ANTX Buy
- Analyst Count
- PYPD 5
- ANTX 2
- Target Price
- PYPD $11.40
- ANTX $2.00
- AVG Volume (30 Days)
- PYPD 175.1K
- ANTX 90.6K
- Earning Date
- PYPD 08-13-2025
- ANTX 08-12-2025
- Dividend Yield
- PYPD N/A
- ANTX N/A
- EPS Growth
- PYPD N/A
- ANTX N/A
- EPS
- PYPD N/A
- ANTX N/A
- Revenue
- PYPD N/A
- ANTX N/A
- Revenue This Year
- PYPD N/A
- ANTX N/A
- Revenue Next Year
- PYPD N/A
- ANTX N/A
- P/E Ratio
- PYPD N/A
- ANTX N/A
- Revenue Growth
- PYPD N/A
- ANTX N/A
- 52 Week Low
- PYPD $2.30
- ANTX $0.87
- 52 Week High
- PYPD $4.42
- ANTX $2.98
- Technical
- Relative Strength Index (RSI)
- PYPD 65.03
- ANTX 52.20
- Support Level
- PYPD $3.30
- ANTX $1.05
- Resistance Level
- PYPD $3.87
- ANTX $1.10
- Average True Range (ATR)
- PYPD 0.14
- ANTX 0.03
- MACD
- PYPD 0.01
- ANTX 0.01
- Stochastic Oscillator
- PYPD 86.84
- ANTX 83.50
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.